Dr. Agarwal on the Tolerability of Apalutamide in mCSPC

(57)

Dr. Morris on OS Data With Apalutamide in Prostate Cancer

(57)

Dr. Saad on the Safety Profile of Apalutamide in M0CRPC

(1:23)

Apalutamide for High-Risk Prostate Cancer | Learn About Clinical Trials

(4:23)

Apalutamide in Metastatic Castration-Sensitive Prostate Cancer (mCSPC): A Case-Based Discussion

(34:48)

TITAN Phase 3 Trial with Apalutamide in Metastatic Castration Sensitive Prostate Cancer

(8:33)

Dr. Bradley on Adverse Events Associated With Enzalutamide and Apalutamide in Prostate Cancer

(1:6)

Dr. Saad on the Clinical Impact of Apalutamide in nmCRPC

(1:46)

Dr. Agarwal on the QoL With Apalutamide in Metastatic Castration-Sensitive Prostate Cancer

(1:46)

Apalutamide in Treating Nonmetastatic CRPC

(5:20)

Awaiting key results for enzalutamide and apalutamide in nmCRPC

(1:55)

ARNEO: Degarelix with apalutamide in high-risk prostate cancer

(7:52)

Dr. Wise on the FDA Approval of Apalutamide in Non-Metastatic CRPC

(44)

Real-world PSA responses to apalutamide or enzalutamide in mCSPC

(2:24)

Apalutamide in combination with abiraterone acetate, docetaxel and prednisone for mCRPC

(5:59)

Apalutamide and the TITAN Clinical Trial

(3:28)

Apalutamide Plus ADT Leads to Survival Benefit in mCSPC

(1:28)

Comparing Apalutamide and Enzalutamide in Real-World Treatment of mCSPC

(8:9)

Apalutamide, ADT Improve Outcomes in High-Risk Prostate Cancer Post-Surgery

(6:12)

Kim N. Chi, MD, speculates on the future role of apalutamide in the treatment of prostate cancer

(1:28)